← Browse by Condition
Medical Condition

transthyretin amyloidosis polyneuropathy

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for transthyretin amyloidosis polyneuropathy sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

  • Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
  • Phase 1–4 studies from early safety trials to post-marketing surveillance
  • NIH, pharmaceutical sponsor, and academic medical center studies worldwide
  • AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 1
1
Phase 2
1
Top Sponsors
YolTech Therapeutics Co., Ltd 1 trial

Recruiting Clinical Trials

NCT06539208 Phase 1, Phase 2
Recruiting

A Phase I/IIa,Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Enrollment
31 pts
Location
China
Sponsor
YolTech Therapeutics Co., Ltd
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology